NCT00004208View on ClinicalTrials.gov

Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2011

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

ATG + CSA

Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)

BEHAVIORAL

Supportive care

Patients randomized to this arm will be treated as outpatients.

Trial Locations (1)

CH-4031

Universitaetsspital-Basel, Basel

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT00004208 - Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter